Expand all sections

Liraglutide

Saxenda

Extended indication

Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activ

Therapeutic value

No estimate possible yet
Registration phase

Registered

Product

Active substance

Liraglutide
Domain

Metabolism and Endocrinology
Reason of inclusion

Indication extension
Main indication

Metabolic diseases
Extended indication

Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with body weight above 60kg and obesity (BMI corresponding to ≥30kg/m2 for adults).
Proprietary name

Saxenda
Manufacturer

Novo Nordisk
Mechanism of action

GLP-1 receptor agonist
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)
Additional comments 
GLP-1 analoog

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
Submission date

February 2020
Expected Registration

June 2021
Orphan drug

No
Registration phase

Registered
Additional comments 
Positieve CHMP-opinie in maart 2021. Publicatie van GVS-advies wordt verwacht in februari 2022.

Therapeutic value

Therapeutic value

No estimate possible yet
Frequency of administration

1 times a day
References 
NCT02918279

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost

€ 1,175.00
References 
GIPdatabank
Additional comments 
In 2018 werd er per patiënt €1.175 vergoed voor het gebruik van liraglutide.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.